Abcam, ab184784, Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal VEGF Receptor 1 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Mouse, Human, Rat, Chinese hamster samples. Cited in 26 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:Y103,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human, Chinese hamster,
Applications:IP, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Based on our results, no splice isoforms can be detected.

Product details:
ab184784 is the carrier-free version of
ab32152
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.
What does low endotoxin mean?
Our low endotoxin, azide-free formats have low endotoxin level (1 EU/mg, determined by the TAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VEGF Receptor 1 also known as FLT-1 is a protein that plays a critical role in the regulation of angiogenesis. Its mass is approximately 180 kDa. FLT-1 is a receptor tyrosine kinase expressed mainly on the surface of endothelial cells but also in monocytes and macrophages. The receptor binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) which initiates a series of signaling cascades important for vascular development and function.
Biological function summary
FLT-1 mediates important cellular responses such as cell migration and proliferation. Although it often functions in conjunction with other receptors like VEGFR-2 FLT-1 has unique binding affinities that modulate the availability of VEGF for other receptors. FLT-1 proteins as part of complex signaling networks actively contribute to maintaining vascular homeostasis and regulating blood vessel permeability.
Pathways
FLT-1 is an important component in the VEGF signaling pathway and also part of the PlGF/VEGF pathway. The receptor serves as a decoy to regulate the amount of VEGF interaction with VEGFR-2 influencing endothelial cell function and vascular permeability. By sequestering VEGF FLT-1 helps maintain the balance in this angiogenic signaling network interacting with proteins like VEGF PlGF and the anti-VEGF agents that target these pathways.
FLT-1 is implicated in cancer and diabetic retinopathy. Overexpression or dysregulation of FLT-1 can contribute to tumor angiogenesis which can enhance tumor growth and metastasis. In diabetic retinopathy abnormal FLT-1 activity affects retinal blood vessels leading to vision impairment. Similar interactions involve VEGFR-2 and other downstream effectors emphasizing the potential of FLT-1 as a therapeutic target for conditions associated with excessive angiogenesis and vascular dysfunction.